Back to search
FDAFDA · Food and drugs·Recall number D-0005-2022

Meclizine HCl Tablets, 25 mg, packaged in 100-count HDPE bottle, Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816, Manufactured by: Aurex laboratories LLC, East Windsor, NJ 08520, NDC 16571-752-01

Published October 13, 2021 · Recall initiated: September 2, 2021

Summary

FDA records drug Class II recall D-0005-2022, published October 13, 2021 and initiated September 2, 2021. Recalling firm: RISING PHARMACEUTICALS; Status: Ongoing; Reported quantity: 1,344 bottles; Lot: Lot # CB21024, Exp 2/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Incorrect Instructions

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RISING PHARMACEUTICALS
Distributor
to be entered
Lot
Lot # CB21024, Exp 2/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Meclizine HCl Tablets, 25 mg, packaged in 100-count HDPE bottle, Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816, Manufactured by: Aurex laboratories LLC, East Windsor, NJ 08520, NDC 16571-752-01 recalled?

Yes. FDA published recall D-0005-2022 on October 13, 2021. Reported hazard: Labeling: Incorrect Instructions

What should I do if I have this product?

Voluntary: Firm initiated · Letter